Monday, November 19, 2018

Dawn of A New Era: Antibody-drug Conjugates in the Treatment of Cancer

Two decades ago, antibody-drug conjugates or ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant...

Why Academia Wasn’t Ready to Build Big Data Systems – A Conversation with Amy Abernethy

Big news hit the pharmaceutical industry in February when Roche Pharmaceuticals announced that it would be acquiring big-data firm Flatiron Health for $1.9 billion. Roche already held a 12% stake in Flatiron, so the total value of the deal--which was completed in early April--will be $2.1 billion, and under the agreement Flatiron would continue its operations as a separate legal...

New Hybrid Cancer Center Model Helps Meet the Demand for Better Quality Care

A new cancer center model is helping meet the demand for better quality cancer care in community settings, and ADC Review | Journal of Antibody-drug Conjugates has an original paper describing the concept. Hybrid academic-community cancer centers began emerging and evolving at several sites in some southern and mid-Atlantic states during the last several years, and in February 2017...

Online Technology Designed to Help Patients Play an Active Role in their Care Improve Outcomes

A randomized clinical trial of 766 patients, funded by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), shows that a simple, web-based, tool that enables patients to report their symptoms in real time, improves outcomes. The online intervention tool was designed to triggers specific alerts to clinicians. Patients with metastatic cancer who used the tool to...

Supplemental Biologics License Application for Obinutuzumab Approved for Previously Untreated Chronic Lymphocytic Leukemia

The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application orsBLA for obinutuzumab (Gazyva®; Genentech/Roche) in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia (CLL). The sBLA adds to the label data from Stage 2 of the CLL11 study showing significant improvements with Gazyva plus chlorambucil across multiple clinical endpoints when...

Majority Elderly Women with Early Stage Breast Cancer may Not Benefit from the Treatment They Receive

Data from a new analysis published early online in Cancer, a peer-reviewed journal of the American Cancer Society has found that while clinical trial data support omitting radiation treatments in elderly women with early stage breast cancer, nearly two-thirds of these women continue to receive it.Results published in 2004 from a large, randomized clinical trial showed that adding radiation...

Companion Diagnostics: Paying a Central Role in the Success of Personalized Medicine

There has been a real revolution in the understanding of molecular biology. This revolution is fueled by the rapid decline in the costs of sequencing, which allowed next-generation sequencing (NGS) assays, previously only seen in research laboratories, to begin making inroads into molecular diagnostics. The wide-ranging capabilities of next-generation sequencing offer extraordinary opportunities for the development and new companion...

Increased Risk of Heart-Related Deaths in Men with Cardiovascular Problems Linked to Prostate Cancer Medications

A new study first published online in the October 29, 2014 issue of BJU International, has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. According to the authors, the findings will help doctors and patients weigh the benefits and risks...

Why a Multidisciplinary Team Approach in Managing Prostate Cancer Makes Sense

Prostate cancer is among the most prevalent cancers in the developed world. It also remains one of the most complex diseases to treat. According to the American Cancer Society prostate cancer is a leading cause of cancer-related deaths. While the advent of PSA (prostate specific antigen) testing has shifted detection from late-stage disease to early-stage disease, it has also...

Breast Cancer in Young Women: Emotional Support Remains Crucial

A deadly disease. You may think you can’t get it. But it can happen to anybody. How to cope? In September 2000, one week before turning 32, Hazel Flynt, a specialist in the study of patient-centered care, crashed into a wall she couldn’t have imagined was in front of her. The mother of a toddler daughter and an infant...

Related articles